Score Overview
Explore the 2021 public Archive ranking →
Where Gilead Sciences Inc has ranked, year by year
Showing 5 years ranking history by HDB Score.
Reached the top 50 on HDB Score in 3 years, the longest run being 3 in a row — but not in 2021.
- GILD
1998: 92.6% · 2021: 88.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 151.28 | — |
1 Year2025-09-29 | $ 109.90 | 37.65% |
5 Years2021-09-29 | $ 59.37 | 154.82% |
10 Years2016-09-29 | $ 54.66 | 176.75% |
20 Years2006-09-29 | $ 11.73 | 12x |
30 Years1996-09-27 | $ 0.58 | 260x |
All Time1992-01-22 | $ 0.43 | 350x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | 30 Years1996-09-27 | All Time1992-01-22 |
|---|---|---|---|---|---|---|---|
| Price | $ 151.28 | $ 109.90 | $ 59.37 | $ 54.66 | $ 11.73 | $ 0.58 | $ 0.43 |
| Return | — | 37.65% | 154.82% | 176.75% | 12x | 260x | 350x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 30.45B | -$ 3.24B | $ 3.17B |
| 2025 | $ 29.44B | $ 8.51B | $ 9.61B |
| 2024 | $ 28.75B | $ 480M | $ 11.56B |
| 2023 | $ 27.11B | $ 5.66B | $ 7.26B |
| 2022 | $ 27.28B | $ 4.59B | $ 6.38B |
| 2021 | $ 27.30B | $ 6.22B | $ 6.52B |
| 2020 | $ 24.68B | $ 123M | $ 7.40B |
| 2019 | $ 22.44B | $ 5.38B | $ 24.35B |
| 2018 | $ 22.12B | $ 5.45B | $ 30.08B |
| 2017 | $ 26.10B | $ 4.62B | $ 25.51B |
| 2016 | $ 30.39B | $ 13.50B | $ 32.38B |
| 2015 | $ 32.63B | $ 18.10B | $ 26.20B |
| 2014 | $ 24.89B | $ 12.10B | $ 11.72B |
| 2013 | $ 11.20B | $ 3.07B | $ 2.13B |
| 2012 | $ 9.70B | $ 2.59B | $ 1.86B |
| 2011 | $ 8.38B | $ 2.80B | $ 9.90B |
| 2010 | $ 7.94B | $ 2.90B | $ 2.09B |
| 2009 | $ 7.01B | $ 2.63B | $ 1.65B |
| 2008 | $ 5.33B | $ 1.97B | $ 1.79B |
| 2007 | $ 4.23B | $ 1.61B | $ 1.17B |
| 2006 | $ 3.02B | -$ 1.18B | $ 936M |
| 2005 | $ 2.02B | $ 813M | $ 2.31B |
| 2004 | $ 1.32B | $ 449M | $ 1.25B |
| 2003 | $ 867M | -$ 72M | $ 707M |
| 2002 | $ 466M | $ 72M | $ 942M |
| 2001 | $ 233M | $ 52M | $ 582M |
| 2000 | $ 195M | -$ 56M | $ 512M |
| 1999 | $ 169M | -$ 66M | $ 294M |
| 1998 | $ 151M | -$ 44M | $ 101M |
| 1997 | $ 132M | -$ 72M | $ 32M |
| 1996 | $ 33M | -$ 21M | $ 132M |
| 1995 | $ 2M | -$ 27M | $ 27M |
| 1994 | $ 4M | -$ 31M | $ 30M |
| 1993 | $ 4M | -$ 25M | $ 13M |
| IPO1992 | $ 4M | -$ 14M | $ 2M |
Gilead Sciences Inc fundamental performance
Between 2005 and 2025, revenue grew from $ 2.02B to $ 29.44B and net income grew from $ 813M to $ 8.51B. Revenue increased in 15 of those 20 years; net income in 11.
Between 1995 and 2025, revenue grew from $ 2M to $ 29.44B and net income went from -$ 27M to $ 8.51B. Revenue increased in 25 of those 30 years; net income in 17.
Gilead Sciences Inc currently holds a 20-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.
Membership
Continue GILD’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
